Success stories
In the context of chronic diseases, the transition from pediatric to adult healthcare system is a critical step for continuity of care, with a significant risk of disruption in the disease management. The SOLAIR study was conducted using using the French healthcare database system (Système National des Données de Santé (SNDS)) on 313 adolescents with severe asthma treated with omalizumab (Xolair®). Using unsupervised learning methods (AI/Machine Learning), four clusters of adolescent/adult transition periods (16-20 years) were identified based on omalizumab exposure and healthcare pathways – medical visits, consumption of other asthma treatments, hospitalizations. The cluster analysis showed that the maintenance of omalizumab treatment might not be as regular as expected during this transition period, with half of the adolescents discontinuing their treatment and insufficient asthma control for nearly half of them. Interestingly, more than half of the children who stopped omalizumab appeared to control their asthma quite well after discontinuation, suggesting remission.
N° T12944822020012 (https://www.health-data-hub.fr/projets/french-cohort-severe-asthmatic-patients-treated-omalizumab-real-life-settings-solair)
Data Controller: Novartis
Data Processor: RCTs
Comité Scientifique : Arnaud Bourdin, Antoine Deschildre, Marc Humbert, Mathieu Molimard, Camille Taillé
ou
Plus d’information : : https://openres.ersjournals.com/content/early/2024/02/15/23120541.00976-2023
